Primary lateral sclerosis: clinical, neurophysiological, and magnetic resonance findings


Abstract

**Objective**—To describe the clinical, neurophysiological, and MRI findings in 10 patients with primary lateral sclerosis (PLS).

**Results**—The course of the disease was very slowly progressive. Spasticity due to upper motor neuron dysfunction was the most prominent sign, but EMG showed slight lower motor neuron signs, such as a mixed pattern on maximal voluntary contraction and enlarged motor unit potentials. One patient had clinically mild lower motor neuron involvement. Central motor conduction times (CMCT) were more prolonged in PLS than in the case in ALS. Minor sensory signs were found on neurophysiological examination, comparable with those in ALS. In four patients serum creatine kinase activity was raised. On MRI cortical atrophy was seen, most pronounced in the precentral gyrus and expanding into the parietal-occipital region.

**Conclusions**—PLS is a distinct clinical syndrome, part of the range of motor neuron diseases. Besides pronounced upper motor neuron symptoms, mild lower motor neuron symptoms can also be found, as well as (subclinical) sensory symptoms. PLS can be distinguished from ALS by its slow clinical course, a severely prolonged MEP, and a more extensive focal cortical atrophy.

(J Neurol Neurosurg Psychiatry 2001;71:615–620)

Keywords: primary lateral sclerosis; motor neuron disease

Primary lateral sclerosis (PLS) is a disorder characterised by spinobulbar spasticity due to upper motor neuron degeneration. It has been a much debated entity in the past, because many reported patients seemed ultimately to have different diseases—for example, amyotrophic lateral sclerosis (ALS), spinal multiple sclerosis, or cervical spondylotic myelopathy. Younger et al revived the syndrome on the basis of pathological observations and modern technical findings.1 In 1992 Pringle et al reported on a group of eight patients with PLS and established clinical and laboratory criteria.2 According to modern views, PLS is considered to be part of the range of motor neuron diseases consisting of primary lateral sclerosis, amyotrophic lateral sclerosis (ALS), and progressive spinal muscular atrophy (PSMA).3–6

Primary lateral sclerosis stands here for a dysfunction of the corticospinal pathway without lower motor neuron involvement. Clinical features include prominent spasticity with only slight weakness in the lower limbs and eventually pseudobulbar symptoms (dysarthria and compulsive laughing or crying). The disease is slowly progressive. Although “pure” PLS remains confined to the spinobulbar tract and spares the lower motor neuron, transitions to ALS have been found.5–7 Pathologically, a selective involvement of the motor cortex is seen with degeneration of the Betz cells and demyelination of the descending motor tracts.5–6 Brain MRI has shown atrophy of the precentral gyrus in many cases.5–7 We present here the clinical and neurophysiological findings in 10 patients with PLS and describe the abnormalities on MRI.

**Materials and methods**

Over a period of 15 years, 10 patients with PLS were seen in the departments of neurology of the University Hospital and the Martini Hospital in Groningen. Diagnosis was in accordance with the criteria set by Pringle et al.2 Nine patients were personally examined by one of us (J K-U); one patient had died, but his medical records could be traced. An extensive serological screening and CSF examination was carried out in all patients.

Motor nerve conduction velocities (MNCVs) were measured according to standard procedures (median nerve normal 50 m/s and peroneal nerve 42 m/s). Sural nerve conduction velocity (SNCV) and response amplitudes were studied with the retrograde method (normal conduction velocity 40–57 m/s, amplitude 5–20 µV). Concentric needle EMG was performed in the tibialis anterior muscle, extensor digitorum communis muscle, and the biceps brachii muscle on the left side.

In eight patients transcranial magnetic stimulation was performed with a Magstim model 200, coil diameter 90 mm, output 80%–100%. Recording was done with surface electrodes for the arm from the abductor pollicis brevis and for the leg from the tibial anterior muscle. All measurements were taken during slight voluntary activation of these muscles. The central motor conduction time (CMCT) was calculated by subtracting the latencies at cervical (C6/C7) or lower lumbar (L4/L5) stimulation from the latencies at cortical stimulation. Normal mean values (SD) of the CMCT during slight activation of the stimulated muscle are for the abductor pollicis brevis.
(5.6 ms (SD 0.9) ms) and for the tibial anterior muscle ((9.5 × L−1.7) ms (SD 1.64) ms; L is body length (m)). Short latency somatosensory evoked responses were determined as described by Chiappa.11 The means (SD) were used as reference values.

In nine patients a cranial MRI was obtained with a Siemens 1.5 Tesla scanner (Magneton Vision). Sagittal T1 weighted (TR/TE 430/12), coronal T2 weighted (TSE TR/TE 3950/99), axial T2 weighted (TSE TR/TE 4000/90), and axial dark fluid (TR/TE 9999/105) images were obtained for seven patients. The MRI of two patients some years previously were re-evaluated. A cervical MRI was obtained for six patients and a myelography for one.

In all patients the degree of disability was scored using the Barthel index and the modified Rankin scale.12 Non-parametric tests (Spearman’s ρ, Mann-Whitney U, ÷2) were used to assess the relations of the following variables: age, age of onset, disease duration, degree of spasticity, presence of pseudobulbar signs, urinary incontinence, serum creatine kinase concentration, CSF protein concentration, and abnormal motor unit potentials on EMG. Because there were no directional hypotheses, two sided tests were used to determine the level of significance (p<0.05).

Results
The group consisted of nine men and one woman. Their clinical features are depicted in table 1. The main finding in all patients was severe spasticity with accompanying corticospinal tract signs such as hyperreflexia, Babinski’s sign, pseudobulbar reflexes, and masseter hyperreflexia. The symptoms started in eight patients in the legs and were asymmetric in five patients. Spasticity was scored according to the modified Ashworth scale: grade 0 (no increase in tone), grade 1 (slight increase in tone, giving a “catch” when the affected part is moved), grade 2 (more pronounced increase in tone, but affected part easily flexed), grade 3 (considerable increase in tone; passive movement difficult), grade 4 (affected part rigid in flexion or extension).13 One patient had atrophy of the first interosseus, abductor digiti minimi, and abductor pollicis muscles in both hands, with normal strength and sensation and without fasciculations. The atrophy had developed very gradually over more than 8 years. An extensive search showed no cause for this abnormality. None of the other patients had clinical signs of lower motor neuron involvement.

Peripheral blood cell count was normal in all patients. Serum values for hepatic and renal function tests, calcium, and phosphate were normal. Creatine kinase was slightly increased in four out of nine patients. Immunoelectrophoresis was normal in nine patients and paraproteinemia was absent. Anti-GM1 antibodies, hexosaminidase concentrations, very long chain fatty acid concentrations, vitamin B12 concentrations, and HTLV-1 antibodies were negative or normal in nine patients and not measured in patient 7. Normal serology or normal CSF in all patients excluded Lues and Borrelia infections. HIV serology was not performed because no patient had risk factors.

Table 1 Clinical features

<table>
<thead>
<tr>
<th>Patient</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>V</td>
<td></td>
</tr>
<tr>
<td>Age of onset (y)</td>
<td>54</td>
<td>45</td>
<td>44</td>
<td>39</td>
<td>31</td>
<td>23</td>
<td>55</td>
<td>30</td>
<td>57</td>
<td>53</td>
</tr>
<tr>
<td>Family history</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Duration in years</td>
<td>6</td>
<td>8</td>
<td>18</td>
<td>7</td>
<td>35</td>
<td>10</td>
<td>6</td>
<td>11</td>
<td>8</td>
<td>18</td>
</tr>
<tr>
<td>First diagnosis</td>
<td>ALS</td>
<td>CM</td>
<td>LS</td>
<td>MS</td>
<td>ALS</td>
<td>LS</td>
<td>Park</td>
<td>MS</td>
<td>ALS</td>
<td>LS</td>
</tr>
<tr>
<td>Diagnostic delay (y)</td>
<td>6</td>
<td>2</td>
<td>0</td>
<td>6</td>
<td>28</td>
<td>0</td>
<td>6</td>
<td>20</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Weakness</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Site of onset</td>
<td>L leg</td>
<td>L leg</td>
<td>Legs</td>
<td>Legs</td>
<td>R arm</td>
<td>Legs</td>
<td>R leg</td>
<td>Legs</td>
<td>Speech</td>
<td>L leg</td>
</tr>
<tr>
<td>Spasticity/Ashworth</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>NT</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>LMN signs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sensory deficit</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pseudobulbar affect</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Urinary incontinence</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Barthel/Rankin scale</td>
<td>16/3</td>
<td>16/3</td>
<td>18/2</td>
<td>20/2</td>
<td>4/5</td>
<td>20/2</td>
<td>11/4</td>
<td>18/2</td>
<td>17/3</td>
<td>17/3</td>
</tr>
<tr>
<td>Medical aids</td>
<td>WCH</td>
<td>WCH</td>
<td>W</td>
<td>-</td>
<td>WCH</td>
<td>-</td>
<td>WCH</td>
<td>W</td>
<td>W</td>
<td>WCH</td>
</tr>
</tbody>
</table>

++=Present; +=absent/negative; NT=not tested; ALS=amyotrophic lateral sclerosis; CM=cervical myelopathy; MS=multiple sclerosis; LS=lateral sclerosis; Park=Parkinson; Ashworth scale 0–4; L MN=lower motor neuron; WCH=wheel chair; W=walker.

Table 2 Laboratory findings

<table>
<thead>
<tr>
<th>Patient</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum chemistry</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
</tr>
<tr>
<td>Creatine kinase</td>
<td>62</td>
<td>25</td>
<td>22</td>
<td>20</td>
<td>22</td>
<td>24</td>
<td>20</td>
<td>24</td>
<td>22</td>
<td>24</td>
</tr>
<tr>
<td>Infectious serologies</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
</tr>
<tr>
<td>Immune-electrophoresis</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>NT</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
</tr>
<tr>
<td>Paraproteinemia</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>Anti GM1 antibodies</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>CSF:</td>
<td>Protein</td>
<td>0.39</td>
<td>0.67</td>
<td>0.48</td>
<td>0.40</td>
<td>0.32</td>
<td>0.53</td>
<td>0.77</td>
<td>0.42</td>
<td>0.74</td>
</tr>
<tr>
<td>OB/NGC index</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
</tr>
<tr>
<td>Cell count</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
<td>Norm</td>
</tr>
</tbody>
</table>

Norm=Normal; -=absent; NT=not tested; OB=oligoclonal bands; CK normal=0–50 u/l; CSF protein normal=<0.55 g/l.

www.jnnp.com
The CSF was normal with the exception of a slightly increased protein concentration in three patients (table 2). The results of the motor nerve conduction velocity (MNCV), needle EMG, motor evoked potential (MEP), and somatosensory evoked potential (SSEP) examinations are presented in table 3. Cranial MRI showed not only conspicuous precentral atrophy but also atrophy in the frontal and parietal-occipital regions (fig 1 and 2). Cervical MRI or myelography was normal for all patients tested.

In the statistical analysis only a few significant results were found. Age of onset was significantly later for patients with pseudobulbar signs (Mann-Whitney p<0.01). In our series, pseudobulbar signs were only present when the onset of the disease occurred at the age of 45 or later. No significant differences in chronological age or duration of the disease were found between these two subgroups. The absence of pseudobulbar signs was associated with the absence of urinary incontinence (χ²=4.26, P<0.05).

<table>
<thead>
<tr>
<th>Patient</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEP CMCT arm Left/right</td>
<td>No response</td>
<td>7.8 (2.4)/7.4 (2.0)</td>
<td>4.9 (-0.8)/4.7 (-1.0)</td>
<td>12.4 (7.5)/9.4 (4.2)</td>
<td>NT</td>
<td>7.2 (1.8)/6.4 (0.9)</td>
<td>NT</td>
<td>8.3 (3.0)/10.7 (5.7)</td>
<td>No response</td>
<td>No response</td>
</tr>
<tr>
<td>CMCT leg Left/right</td>
<td>No response</td>
<td>No response</td>
<td>24.8 (5.2)/22.4 (3.7)</td>
<td>22.2 (3.8)/23.5 (4.6)</td>
<td>NT</td>
<td>23.7 (4.5)/20.9 (2.8)</td>
<td>NT</td>
<td>35.2 (12.0)/28.9 (7.9)</td>
<td>No response</td>
<td>No response</td>
</tr>
<tr>
<td>MNCV arm/leg</td>
<td>51 / 41</td>
<td>49 / 37</td>
<td>39 / 41</td>
<td>48 / 43</td>
<td>55 / 46</td>
<td>55 / 45</td>
<td>52 / 38</td>
<td>57 / 42</td>
<td>53 / 46</td>
<td></td>
</tr>
<tr>
<td>EMG: Spontaneous activity</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SSEP N20 Left/right</td>
<td>23.1 (4.0)/22.3 (3.2)</td>
<td>22.4 (3.3)/22.1 (3.0)</td>
<td>21.0 (2.0)/21.1 (2.1)</td>
<td>22.4 (3.3)/21.9 (2.8)</td>
<td>NT</td>
<td>20.2 (1.2)/21.1 (2.1)</td>
<td>NT</td>
<td>23.1 (4.0)/23.0 (3.9)</td>
<td>21.1 (2.1)/21.1 (2.1)</td>
<td>NT</td>
</tr>
<tr>
<td>CSCT arm Left/right</td>
<td>7.0 (1.8)</td>
<td>6.9 (1.8)</td>
<td>Not obtained/7.8 (2.3)</td>
<td>5.7 (0.9)/5.2 (0.5)</td>
<td>7.4 (2.2)/6.7 (1.7)</td>
<td>NT</td>
<td>5.5 (1.0)/5.7 (1.1)</td>
<td>NT</td>
<td>8.1 (2.7)/8.3 (2.8)</td>
<td>7.0 (1.8)/6.8 (1.6)</td>
</tr>
<tr>
<td>P40 Left/right</td>
<td>46.4 (5.5)/44.6 (4.4)</td>
<td>46.6 (4.9)/48.2 (5.9)</td>
<td>55.6 (9.4)/60.4 (12.6)</td>
<td>51.8 (7.5)/50.6 (6.7)</td>
<td>46.4 (3.6)/44.2 (2.3)</td>
<td>NT</td>
<td>45.8 (3.8)/45.8 (3.8)</td>
<td>NT</td>
<td>57.2 (12.0)/41.6 (4.2)</td>
<td>No response</td>
</tr>
<tr>
<td>CSCT leg Left/right</td>
<td>20.8 (2.9)/20.2 (2.5)</td>
<td>21.0 (2.7)/21.0 (2.5)</td>
<td>Not obtained/31.6 (10.4)</td>
<td>27.6 (7.5)/25.8 (6.1)</td>
<td>NT</td>
<td>20.4 (1.8)/17.4 (0.5)</td>
<td>NT</td>
<td>18.8 (0.6)/17.4 (0.5)</td>
<td>NT</td>
<td>No response</td>
</tr>
<tr>
<td>SNCV leg</td>
<td>48</td>
<td>40</td>
<td>38</td>
<td>40</td>
<td>40</td>
<td>40</td>
<td>40</td>
<td>40</td>
<td>40</td>
<td>40</td>
</tr>
<tr>
<td>SNRA</td>
<td>13.6</td>
<td>3.8</td>
<td>5.7</td>
<td>6.7</td>
<td>NT</td>
<td>5.8</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
</tbody>
</table>

+=Present; -=absent; NT=not tested; ( )=SD; SSEP=somatosensory evoked potential (ms); MEP=monomorphemic evoked potential (ms); MNCV=median nerve conduction velocity median and peroneal nerve (ms); SNCV=sensory nerve conduction velocity sural nerve (ms); SNRA=sensory nerve response amplitude (µV).
Discussion

The diagnosis PLS is made on clinical grounds. Commonly used criteria are adult onset, negative family history, gradual progression, spasticity with paresis of the legs for more than 3 years, and dysfunction clinically limited to the corticospinal tracts. Differential diagnosis of PLS includes many spinal cord syndromes. In all our patients the normal CSF or the absence of typical white matter densities on MRI ruled out chronic spinal MS. Infections such as HTLV-1, neuroborreliosis, or neurosyphilis were excluded by the normal serology or the normal CSF. Subacute combined degeneration of the cord due to vitamin B12 deficiency and metabolic diseases (adrenoleucodystrophy, hexosaminidase deficiency, cerbrotendinous xanthomatosis) were excluded in nine patients. Foramen magnum lesions or compression of the cord was excluded on clinical grounds and confirmed by cervical MRI in seven patients. Hereditary spastic paralysis was ruled out by a meticulous family history. PLS may be associated with malignancies but in our group these were absent.

PLS usually is equally distributed between both sexes. In our series, however, there was a male preponderance. Median age of onset was 44.5 years. In all patients the clinical course was slowly progressive, from 6 to 35 years. There was no correlation between the duration of the disease and any of the clinical, laboratory, or EMG data. Three patients were diagnosed as PLS, but seven were at first misdiagnosed: three as ALS, two as multiple sclerosis, one as Parkinson’s disease, and one as cervical compression myelopathy. It took between 2 and 28 years before the correct diagnosis was made. All patients had difficulties in walking, but only two patients had manifest weakness in the legs. In all cases the stiff, awkward, wooden way of walking was due to extreme spasticity. According to the Ashworth scale, seven patients were in grade 2, and two in grade 3. No correlation was found between the Ashworth scale and any of the other data. Five patients had bouts of unprovoked laughing and crying. This group with pseudobulbar signs differed significantly from the five others by their older age of onset. The patients without pseudobulbar signs had no urinary incontinence. One patient had clinical signs of lower motor neuron involvement—namely, an atrophy of the muscles of both hands, without weakness, fasciculations, or sensory loss. This atrophy had been present for more than 8 years and was very slowly progressive. No atrophy was present in other parts of the body. In the literature a few similar patients have been described. Three of our patients had urinary incontinence, probably due to bladder hyperreflexia.

On detailed neuro-psychological evaluation, mild cognitive impairment has been found in PLS, especially in frontal lobe function and memory. Our patients had no clinical signs of intellectual deterioration.

The Barthel index (BI) is a disability score; patients with a score of less than 17 are unable to live independently. The modified Rankin scale (MRS) measures handicap; a score of 2 or more means dependency. Our patients with a BI/MRS=20/2 could walk; the group of about 18/2 had a rollator, the others a wheelchair. Two patients were severely handicapped; these were the only ones with manifest loss of strength. Some patients had a remarkably good score even after many years of illness. This is by contrast with patients with ALS where the increase in dependency is measured in months.

Serum creatine kinase may be increased in patients with ALS or PSMA, but no increase has ever been reported in patients with PLS. It was slightly increased in four of nine of our patients. An increased creatine kinase did not correlate with any of the clinical or EMG data. Protein concentrations in CSF are increased in 20%-30% of patients with ALS. Little is known about the CSF in patients with PLS, although an increased protein concentration has been mentioned. Three of our patients had an increased CSF protein.

Cortically evoked motor potentials are often absent in patients with PLS. When present, the central motor conduction time (CMCT) may be considerably prolonged, two to three times normal, by contrast with ALS where CMCT is normal or only slightly delayed. In three of our patients MEPs could not be elicited in the arms and legs, and in one only in the arms. Two patients had a normal CMCT to the arms (<2 SD); in the others CMCT was prolonged in arms and legs. In the legs this prolongation varied from 2.9 to 12.0 SD (mean 5.6 SD). The difference in CMCT between PLS and ALS is not easy to explain. Both disorders are due to the death of large pyramidal neurons in the cortex. In PLS the very protracted course (compared with ALS) may ultimately cause secondary demyelination of the pyramidal tracts, thus leading to a prolonging of the CMCT. We found considerable asymmetry for the CMCT in some patients; this has been mentioned before. The lower motor neuron remains spared in PLS, although occasionally slight signs of denervation in the EMG are found. None of our patients had acute denervation potentials but in four patients enlarged motor unit potentials (MUPs) and a mixed pattern on maximal voluntary contraction were present. These may be considered as signs of chronic denervation caused by slow lower motor neuron loss. There was no correlation between the presence of enlarged mups and the clinical or laboratory data of the patients.

Motor nerve conduction velocity in PLS is normal or prolonged. More than half of the patients in our group had slightly prolonged conduction velocities or values near the lower limit of normal in both upper and lower limbs. Slowing of MNCV has been found in patients with ALS where a preferential degeneration of the fast conducting myelinated axons in the peripheral nerve is presumed. The MNCV findings in our patients are comparable with those found in ALS.
Somatosensory evoked potentials in patients with PLS are reported to be normal or prolonged. We found at stimulation of the median nerve in three patients a prolonged central sensory conduction time (CSTC) (>2 SD). No responses could be obtained of the peroneal nerve in one patient. In the others CSTC was normal (two patients) or prolonged (from 2.5 to 10.4 SD, mean 5.4 SD). Despite this, the sensory system was clinically normal in all patients. In three patients no values were obtained in the arms or legs because of a lack of reproducible cervical or lumbar responses. In five patients the peripheral sensory system was tested. Sensory nerve response amplitude (SNRA) was diminished in one patient but normal in the others. Sensory nerve conduction velocity was near the lower limit of normal in all patients. On pathological examination the sensory system is normal in PLS, especially in all patients. On pathological examination the lower motor neuron signs, the better the prognosis.

Emil Heinrich Du Bois-Reymond
(1818–96)

This distinguished physiologist is remembered for two dissimilar contributions: he was a founder of electrophysiology of nerve and muscle; and he described his own migraine.

Du Bois-Reymond first discovered that the peripheral passage of a nerve impulse was accompanied by an electrical discharge, the action potential. After Matteucci, whose work he disparaged, he is often regarded as the founder of electrophysiology.

Du Bois-Reymond was born and studied medicine in Berlin. His father was a watchmaker in the Swiss canton Neuchatel but then moved to Berlin as a civil servant. Emil became a student of Johannes Müller, working with him from 1841 until Müller’s death in 1858. After years of industrious study, he succeeded him to the Chair of Physiology. At that time he was in close contact with Helmholz, Brücke, and Ludwig, liaisons that culminated in the foundation of a new institute of physiology in Berlin in 1877. Du Bois-Reymond was the chief for 20 years.

He was described in somewhat antiquated terms, a materialistic, and a mechanical physiologist. Du Bois-Reymond invented a refined sensitive nerve galvanometer and a stimulus producing induction coil. He showed an electric current in muscle (Muskstrom). It was, he thought, owing to a stimulus producing induction coil. He also experimented with Faradic stimulation.

Du Bois-Reymond is also well known for his views on the pathogenesis of migraine. Before his time, Robert Whytt had given an exposition of the spasm and relaxation of small blood vessels in migraine that fore-shadowed the vasospastic theories of Latham. Latham had initiated the vascular hypothesis and explained it as: “a contraction of the blood vessels of the brain, and so diminished supply of blood, produced by the excited action of the sympathetic; and that the exhaustion of the sympathetic following on this excitement causes the dilatation of the vessels and the headache.”

This topic seems remote from the electrophysiological work of Du Bois-Reymond, but his account in 1860 displays a personal stake: “a Tetanus takes place in the muscular coats of the vessels of the affected half of the head; in other words a Tetanus of the cervical portion of the sympathetic.”

He confirmed Matteucci’s observation that during tetanus, the resting current flowing from an intact to an injured region is decreased and this negative variation was composed of a series of individual variations. This is called the negative variation (negative Schwankung) of Du Bois-Reymond. It now corresponds to variation in the action potential.

He investigated physiological tetanus in 1850 and employed in his work the galvanometer. By this means he defined what he called electrotonus, the potential changes produced by an externally applied current; he also experimented with Faradic stimulation.

Du Bois-Reymond was the founder of electrophysiology. Before his time, Robert Whytt had given an exposition of the spasm and relaxation of small blood vessels in migraine that fore-shadowed the vasospastic theories of Latham. Latham had initiated the vascular hypothesis and explained it as: “a contraction of the blood vessels of the brain, and so diminished supply of blood, produced by the excited action of the sympathetic; and that the exhaustion of the sympathetic following on this excitement causes the dilatation of the vessels and the headache.”

This is called the negative variation (negative Schwankung) of Du Bois-Reymond. It now corresponds to variation in the action potential.

This account is of interest showing the remission after an attack; and enophthalmos or miosis, and the red eye, which we would associate with cluster headache. He also deduced both the vascular component of the headache phase, and the role of the sympathetic nerves in inducing vascular constriction. Later, in 1873, Edward Living in his classic text accepted that dilatation of the arteries might explain the headache, but like Gowers, Living rejected the vascular theory as explanation of the varied content of the aura, its bilaterality in certain patients, and the vegetative symptoms throughout the body, and the changes in patterns of attacks. Living regarded it as a “nerve storm.”

“a form of centrencephalic seizure, the activity of which is projected rostrally upon the cerebral hemispheres, and peripherally via the ramifications of the autonomic nervous system . . .”

In explaining his nerve storm theory Living considered migraine along with other “neuroses” to be: “a primary and often hereditary disposition of the nervous system itself; this consists in a tendency to the irregular accumulation and discharge of the nerve force . . .”

Time has shown that Living’s and Gowers’ theories are closer to the truth than du Bois Reymond’s, though we still do not understand the initial mechanism.

J M S PEARCE
304 Beverley Road, Anlaby, Hull HU10 7BG, UK
jmspearce@freenet.co.uk
Primary lateral sclerosis: clinical, neurophysiological, and magnetic resonance findings
J Kuipers-Upmeijer, A E J de Jager, J M Hew, J W Snoek and T W van Weerden

J Neurol Neurosurg Psychiatry 2001 71: 615-620
doi: 10.1136/jnnp.71.5.615

Updated information and services can be found at:
http://jnnp.bmj.com/content/71/5/615

References
This article cites 27 articles, 7 of which you can access for free at:
http://jnnp.bmj.com/content/71/5/615#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Motor neurone disease (302)
Neuromuscular disease (1311)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/